基于CRISPR-Cas12a的液体活检技术:大规模临床应用面临的挑战
本文综述CRISPR-Cas12a液体活检技术,聚焦血液、尿液、脑脊液等七种临床体液,分析不同基质的技术难点与适配策略。文章总结检测方法性能差异及临床应用场景,指出仅提高分析灵敏度不足以支撑大规模临床应用,方法稳健性、结果可重复性和临床可解释性仍是关键制约因素。
要点
- CRISPR-Cas12a具备序列特异性识别与反式切割信号放大,适合低丰度靶标检测。
- 液体活检临床应用受靶标丰度极低、复杂基质抑制及前分析阶段高变异限制。
- 方法稳健性、结果可重复性和临床可解释性是临床转化的关键制约因素。
核心结论
- 仅提高分析灵敏度不足以支撑CRISPR-Cas12a液体活检的大规模临床应用。
- 检测方法稳健性、结果可重复性和临床可解释性仍是限制其临床转化的关键因素。
研究设计与样本
- 本文为综述,总结CRISPR-Cas12a的机制。
- 围绕血液、尿液、脑脊液等七种代表性临床生物体液,分析不同基质的技术难点与适配策略。
主要发现
- CRISPR-Cas12a结合序列特异性识别与反式切割信号放大,在低丰度靶标检测中具有技术优势和转化潜力。
- 综述总结了不同生物体液中检测方法的性能差异及最合理的临床应用场景。
临床怎么用
- 面向临床转化,应同时关注方法稳健性、结果可重复性与临床可解释性,而非仅追求分析灵敏度。
局限性
- 本文为综述,未报告原始研究数据。
- 仅基于现有研究进行初步探讨,未来发展方向仍需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liquid biopsy technology, which enables the acquisition of tumor-related biomarkers in a minimally invasive and reproducible manner, has been widely applied in clinical scenarios such as early tumor detection, treatment response assessment, minimal residual disease (MRD) monitoring, and recurrence surveillance. However, its clinical utility is still limited by the extremely low abundance of clinically relevant targets, the inhibitory effects of complex matrices, and the high variability in pre-analytical stages. As a next-generation programmable nucleic acid diagnostic platform, CRISPR-Cas12a combines the unique mechanisms of sequence-specific recognition and trans-cleavage signal amplification, demonstrating significant technical advantages and translational potential in the detection of low-abundance targets in liquid biopsies. Nevertheless, a mere improvement in analytical sensitivity is insufficient to support its large-scale clinical application; the robustness of detection methods, the reproducibility of results, and clinical interpretability remain the key factors currently restricting its clinical translation. This review summarizes the mechanism of CRISPR-Cas12a. Focusing on seven representative clinical biofluids, including blood, urine, and cerebrospinal fluid, it analyzes the technical difficulties and adaptation strategies associated with different matrices, and summarizes the performance differences of detection methods alongside the most clinically rational application scenarios across various biofluids. Furthermore, it explores the primary bottlenecks this technology faces when transitioning from laboratory proof-of-concept to routine clinical application, and provides a preliminary discussion on its future development directions based on existing research. Ultimately, this review aims to provide a reference for promoting the clinical translation of CRISPR-Cas12a liquid biopsy technologies and the broader implementation of precision medicine.
引用
- Zhang Y, Lin X, Shi H, et al. CRISPR-Cas12a-based liquid biopsy technology: challenges in large-scale clinical application. Clin Chim Acta. 2026. PMID: 42379464. doi:10.1016/j.cca.2026.121210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。